Antitumor T cell responses in bladder cancer are directed against a limited set of antigens and are modulated by regulatory T cells and routine treatment approaches

International Journal of Cancer

Volumn 133, Issue 9, 2013, Pages 2145-2156

  Horn, Thomas ^a,b   Grab, Jessica ^a   Schusdziarra, Julia ^a   Schmid, Sebastian ^a   Maurer, Tobias ^a   Nawroth, Roman ^a   Wolf, Petra ^c   Pritsch, Maria ^b   Gschwend, Jürgen E ^a   Kübler, Hubert R ^a   Beckhove, Philipp ^b  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^b GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^c TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

regulatory T cells; tumor associated antigen; tumor reactive T cells; urothelial cancer

Indexed keywords

CISPLATIN; EPIDERMAL GROWTH FACTOR RECEPTOR; GAMMA INTERFERON; GEMCITABINE; PACLITAXEL; TUMOR ANTIGEN;

ANTIGEN SPECIFICITY; ARTICLE; BLADDER CANCER; CELL PROLIFERATION; CONTROLLED STUDY; CYSTECTOMY; CYTOMETRY; EFFECTOR CELL; ENZYME LINKED IMMUNOSPOT ASSAY; FLUORESCENCE ANALYSIS; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSPECTIVE STUDY; REGULATORY T LYMPHOCYTE; TRANSITIONAL CELL CARCINOMA; TRANSURETHRAL RESECTION;

REGULATORY T CELLS; TUMOR-ASSOCIATED ANTIGEN; TUMOR-REACTIVE T CELLS; UROTHELIAL CANCER;

AGED; ANTIGENS, NEOPLASM; CASE-CONTROL STUDIES; ENZYME-LINKED IMMUNOSPOT ASSAY; FLOW CYTOMETRY; HUMANS; INTERFERON-GAMMA; LYMPHATIC METASTASIS; LYMPHOCYTE ACTIVATION; MALE; PROSTATIC NEOPLASMS; T-LYMPHOCYTES; T-LYMPHOCYTES, CYTOTOXIC; T-LYMPHOCYTES, REGULATORY; UROLOGIC NEOPLASMS;

EID: 84881538095     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.28233     Document Type: Article

References (50)

1. Schreiber RD, Old LJ, Smyth MJ,. Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion. Science 2011; 331: 1565-70.
2. Choi C, Witzens M, Bucur M, et al. Enrichment of functional CD8 memory T cells specific for MUC1 in bone marrow of patients with multiple myeloma. Blood 2005; 105: 2132-4.
3. Domschke C, Schuetz F, Ge Y, et al. Intratumoral cytokines and tumor cell biology determine spontaneous breast cancer-specific immune responses and their correlation to prognosis. Cancer Res 2009; 69: 8420-8.
4. Muller-Berghaus J, Ehlert K, Ugurel S, et al. Melanoma-reactive T cells in the bone marrow of melanoma patients: association with disease stage and disease duration. Cancer Res 2006; 66: 5997-6001.
5. Schirrmacher V, Feuerer M, Fournier P, et al. T-cell priming in bone marrow: the potential for long-lasting protective anti-tumor immunity. Trends Mol Med 2003; 9: 526-34.
6. Mlecnik B, Tosolini M, Kirilovsky A, et al. Histopathologic-based prognostic factors of colorectal cancers are associated with the state of the local immune reaction. J Clin Oncol 2011; 29: 610-18.
7. Galon J, Costes A, Sanchez-Cabo F, et al. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science 2006; 313: 1960-4.
8. Halama N, Michel S, Kloor M, et al. Localization and density of immune cells in the invasive margin of human colorectal cancer liver metastases are prognostic for response to chemotherapy. Cancer Res 2011; 71: 5670-7.
9. Sato E, Olson SH, Ahn J, et al. Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer. Proc Natl Acad Sci USA 2005; 102: 18538-43.
10. Gao Q, Qiu SJ, Fan J, et al. Intratumoral balance of regulatory and cytotoxic T cells is associated with prognosis of hepatocellular carcinoma after resection. J Clin Oncol 2007; 25: 2586-93.
11. Salama P, Phillips M, Grieu F, et al. Tumor-infiltrating FOXP3+ T regulatory cells show strong prognostic significance in colorectal cancer. J Clin Oncol 2009; 27: 186-92.
12. Hodi FS, O'Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010; 363: 711-23.
13. Curiel TJ, Coukos G, Zou L, et al. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med 2004; 10: 942-9.
14. Hori S, Nomura T, Sakaguchi S,. Control of regulatory T cell development by the transcription factor Foxp3. Science 2003; 299: 1057-61.
15. Nummer D, Suri-Payer E, Schmitz-Winnenthal H, et al. Role of tumor endothelium in CD4+ CD25+ regulatory T cell infiltration of human pancreatic carcinoma. J Natl Cancer Inst 2007; 99: 1188-99.
16. Hiraoka N, Onozato K, Kosuge T, et al. Prevalence of FOXP3+ regulatory T cells increases during the progression of pancreatic ductal adenocarcinoma and its premalignant lesions. Clin Cancer Res 2006; 12: 5423-34.
17. Busse A, Asemissen A, Nonnenmacher A, et al. Systemic immune tuning in renal cell carcinoma: favorable prognostic impact of TGF-beta1 mRNA expression in peripheral blood mononuclear cells. J Immunother 2011; 34: 113-19.
18. Cesana GC, DeRaffele G, Cohen S, et al. Characterization of CD4+CD25+ regulatory T cells in patients treated with high-dose interleukin-2 for metastatic melanoma or renal cell carcinoma. J Clin Oncol 2006; 24: 1169-77.
19. Finke JH, Rini B, Ireland J, et al. Sunitinib reverses type-1 immune suppression and decreases T-regulatory cells in renal cell carcinoma patients. Clin Cancer Res 2008; 14: 6674-82.
20. Griffiths RW, Elkord E, Gilham DE, et al. Frequency of regulatory T cells in renal cell carcinoma patients and investigation of correlation with survival. Cancer Immunol Immunother 2007; 56: 1743-53.
21. Miller AM, Lundberg K, Ozenci V, et al. CD4+CD25high T cells are enriched in the tumor and peripheral blood of prostate cancer patients. J Immunol 2006; 177: 7398-405.
22. Ge Y, Domschke C, Stoiber N, et al. Metronomic cyclophosphamide treatment in metastasized breast cancer patients: immunological effects and clinical outcome. Cancer Immunol Immunother 2012; 61: 353-62.
23. Samy ET, Parker LA, Sharp CP, et al. Continuous control of autoimmune disease by antigen-dependent polyclonal CD4+CD25+ regulatory T cells in the regional lymph node. J Exp Med 2005; 202: 771-81.
24. Bonertz A, Weitz J, Pietsch DH, et al. Antigen-specific Tregs control T cell responses against a limited repertoire of tumor antigens in patients with colorectal carcinoma. J Clin Invest 2009; 119: 3311-21.
25. Hadaschik B, Su Y, Huter E, et al. Antigen specific T-cell responses against tumor antigens are controlled by regulatory T cells in patients with prostate cancer. J Urol 2012; 187: 1458-65.
26. Siegel R, Naishadham D, Jemal A,. Cancer statistics, 2012. CA Cancer J Clin 2012; 62: 10-29.
27. Stein JP, Lieskovsky G, Cote R, et al. Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1,054 patients. J Clin Oncol 2001; 19: 666-75.
28. Sharma P, Shen Y, Wen S, et al. CD8 tumor-infiltrating lymphocytes are predictive of survival in muscle-invasive urothelial carcinoma. Proc Natl Acad Sci USA 2007; 104: 3967-72.
29. Sharma P, Gnjatic S, Jungbluth AA, et al. Frequency of NY-ESO-1 and LAGE-1 expression in bladder cancer and evidence of a new NY-ESO-1 T-cell epitope in a patient with bladder cancer. Cancer Immun 2003; 3: 19.
30. Marits P, Karlsson M, Sherif A, et al. Detection of immune responses against urinary bladder cancer in sentinel lymph nodes. Eur Urol 2006; 49: 59-70.
31. Breslow N, Chan CW, Dhom G, et al. Latent carcinoma of prostate at autopsy in seven areas. The International Agency for Research on Cancer, Lyons, France. Int J Cancer 1977; 20: 680-8.
32. Melief CJ, van der Burg SH,. Immunotherapy of established (pre)malignant disease by synthetic long peptide vaccines. Nat Rev Cancer 2008; 8: 351-60.
33. Stadler WM, Lerner SP, Groshen S, et al. Phase III study of molecularly targeted adjuvant therapy in locally advanced urothelial cancer of the bladder based on p53 status. J Clin Oncol 2011; 29: 3443-9.
34. Shariat SF, Ashfaq R, Karakiewicz PI, et al. Survivin expression is associated with bladder cancer presence, stage, progression, and mortality. Cancer 2007; 109: 1106-13.
35. Dyrskjot L, Zieger K, Kissow Lildal T, et al. Expression of MAGE-A3, NY-ESO-1, LAGE-1 and PRAME in urothelial carcinoma. Br J Cancer 2012; 107: 116-22.
36. Bergeron A, Picard V, LaRue H, et al. High frequency of MAGE-A4 and MAGE-A9 expression in high-risk bladder cancer. Int J Cancer 2009; 125: 1365-71.
37. Simms MS, Hughes OD, Limb M, et al. MUC1 mucin as a tumour marker in bladder cancer. BJU Int 1999; 84: 350-2.
38. Gohji K, Okamoto M, Kitazawa S, et al. Heparanase protein and gene expression in bladder cancer. J Urol 2001; 166: 1286-90.
39. Wulfing C, Machiels JP, Richel DJ, et al. A single-arm, multicenter, open-label phase 2 study of lapatinib as the second-line treatment of patients with locally advanced or metastatic transitional cell carcinoma. Cancer 2009; 115: 2881-90.
40. Lae M, Couturier J, Oudard S, et al. Assessing HER2 gene amplification as a potential target for therapy in invasive urothelial bladder cancer with a standardized methodology: results in 1005 patients. Ann Oncol 2010; 21: 815-19.
41. Gardmark T, Wester K, De la Torre M, et al. Analysis of HER2 expression in primary urinary bladder carcinoma and corresponding metastases. BJU Int 2005; 95: 982-6.
42. Sanchini MA, Gunelli R, Nanni O, et al. Relevance of urine telomerase in the diagnosis of bladder cancer. JAMA 2005; 294: 2052-6.
43. Lin Y, Miyamoto H, Fujinami K, et al. Telomerase activity in human bladder cancer. Clin Cancer Res 1996; 2: 929-32.
44. Muller M, Heine B, Heicappell R, et al. Telomerase activity in bladder cancer, bladder washings and in urine. Int J Oncol 1996; 9: 1169-73.
45. Schmitz-Winnenthal FH, Volk C, Z'Graggen K, et al. High frequencies of functional tumor-reactive T cells in bone marrow and blood of pancreatic cancer patients. Cancer Res 2005; 65: 10079-87.
46. Moodie Z, Price L, Gouttefangeas C, et al. Response definition criteria for ELISPOT assays revisited. Cancer Immunol Immunother 2010; 59: 1489-501.
47. Schmitz-Winnenthal H, Pietsch DH, Schimmack S, et al. Chronic pancreatitis is associated with disease-specific regulatory T-cell responses. Gastroenterology 2010; 138: 1178-88.
48. Mahnke YD, Schwendemann J, Beckhove P, et al. Maintenance of long-term tumour-specific T-cell memory by residual dormant tumour cells. Immunology 2005; 115: 325-36.
49. Zitvogel L, Kepp O, Kroemer G,. Immune parameters affecting the efficacy of chemotherapeutic regimens. Nat Rev Clin Oncol 2011; 8: 151-60.
50. Galluzzi L, Senovilla L, Zitvogel L, et al. The secret ally: immunostimulation by anticancer drugs. Nat Rev Drug Discov 2012; 11: 215-33.